Stroma Biosciences, Ltd, a Cambridge based oncology company today announced the appointment of Dr John Beadle as Executive Chairman. Dr Beadle, who previously held the role of CEO at PsiOxus Therapeutics, joins the Stroma Board at a critical time for growth of the company.
Dr Beadle stated: “I have been impressed by the co-culture-based discovery platform developed at Stroma and its broad commercial potential. Applying this we have already identified important new targets based upon stromal signaling. I look forward to working with the team at Stroma to develop novel therapies that will exploit these non-tumor cell targets for the treatment of different cancers.”
Dr Beadle has over 30 years’ experience in the pharmaceutical and biotech industries. He was a Co-Founder, Board Director and Chief Medical Officer at Powdermed, a DNA vaccine company which was acquired by Pfizer in 2006. He was then Entrepreneur in Residence at Imperial Innovations and the founding CEO of PsiOxus Therapeutics, a clinical stage cancer gene therapy company. John’s prior pharmaceutical career include roles at GlaxoSmithKline as VP of Global Medical Operations and at Pfizer as Vaccines Site Head. John obtained his medical degree at the University of Witwatersrand and his MBA from the London Business School.
“It is a great pleasure to welcome Dr Beadle to Stroma Biosciences. He brings exceptional experience and expertise related to cancer drug development and biotech company building. His expertise adds to the excellent scientific team as well as to the accomplished Board,” stated, Michael Salako, Investment Director from Start Codon and Board Director at Stroma.